EVIIVE is a Swiss biotech company pioneering the next generation of blood-based diagnostics through high-dimensional analysis of extracellular vesicles (EVs). Our mission is to unlock the immune system’s hidden signals to guide more precise, personalized treatment decisions — starting with immunotherapy in cancer.
At EVIIVE, we believe every patient deserves a biomarker that works for them.
Spun out from research at the University of Zurich, we’ve built a proprietary platform that profiles single EVs with exceptional resolution, revealing real-time immune dynamics that traditional biomarkers miss. Our technology is designed to work from just a small volume of plasma, enabling truly non-invasive diagnostics with clinical-grade performance.
We are a multidisciplinary team of scientists, clinicians, and entrepreneurs, working at the intersection of immunology, data science, and translational medicine. With strong academic roots, a growing IP portfolio, and partnerships across pharma and academia, we are rapidly advancing toward clinical implementation.
